Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. Felwick
Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Related publications
Systematic Review With Meta-Analysis: The Efficacy and Safety of CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Α Agent (Infliximab), in Inflammatory Bowel Diseases
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Review Article: Consensus Statements on Therapeutic Drug Monitoring of Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Diseases
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Tumor Necrosis Factor Alpha in Inflammatory Bowel Disease.
Gut
Gastroenterology
THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry
Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab
Gastroenterologie a Hepatologie
Hepatology
Gastroenterology
Infliximab (Anti–Tumor Necrosis Factor Α Antibody)
Archives of Dermatology
Cost-Of-Illness of Inflammatory Bowel Disease Patients Treated With Anti-Tumour Necrosis Factor: A French Large Single-Centre Experience
United European Gastroenterology Journal
Oncology
Gastroenterology
Editorial: Anti-Tumour Necrosis Factor Α Antibodies - Can Efficacy Be Regained?
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
